Government-Owned Inventions; Availability for Licensing, 51970 [2018-22360]

Download as PDF 51970 Federal Register / Vol. 83, No. 199 / Monday, October 15, 2018 / Notices Place: National Institutes of Health, Rockledge 6700, Room 3185, MSC 6908, 6700B Rockledge Drive, Bethesda, MD 20817 (Telephone Conference Call). Contact Person: Barbara J Thomas, Ph.D., Scientific Review Officer, Scientific Review Branch, National Human Genome Research Institute, National Institutes of Health, 5635 Fishers Lane, Ste. 4076, MSC 9306, Bethesda, MD 20892–9306, 301–402–0838, barbara.thomas@nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.172, Human Genome Research, National Institutes of Health, HHS) Dated: October 5, 2018. Sylvia L. Neal, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2018–22315 Filed 10–12–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing in the U.S. to achieve expeditious commercialization of results of federally-funded research and development. FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by emailing the indicated licensing contact at the National Heart, Lung, and Blood, Office of Technology Transfer and Development Office of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892–2479; telephone: 301–402–5579. A signed Confidential Disclosure Agreement may be required to receive any unpublished information. SUPPLEMENTARY INFORMATION: Technology description follows. khammond on DSK30JT082PROD with NOTICES SUMMARY: Lentiviral Protein Delivery System for RNA-Guided Genome Editing Available for licensing and commercial development is an HIV–1based lentiviral vector system for gene correction strategies involving a homologous recombination with a variation of the CRISPR/Cas9 system. Other such lentivirus-based vectors encode a guide RNA, which contains a specific sequence that recognizes a target gene, and a Cas9 endonuclease, which cuts at the specific site. Such systems are being explored as potential VerDate Sep<11>2014 21:34 Oct 12, 2018 Jkt 247001 therapies for certain hereditary diseases (e.g., sickle-cell disease). However, such systems present some problems due to constitutive expression of Cas9 endonuclease in lentiviral vectortransduced cells and the large size of the Cas9 gene. The variation of this invention delivers the Cas9 endonuclease directly, instead of the gene encoding the protein. This system comprises (a) a lentivirus vector particle comprising a lentiviral genome which encodes at least one guide RNA sequence that is complementary to a first DNA sequence in a host cell genome, (b) a Cas9 protein, and optionally (c) a donor nucleic acid molecule comprising a second DNA sequence. In addition, the invention provides a host cell comprising the foregoing system, as well as a method of altering a DNA sequence in a host cell comprising contacting a host cell with the foregoing system. Alternatively, the invention also provides a fusion protein comprising a Cas9 protein and a cyclophilin A (CypA) protein, wherein the fusion protein binds to the lentivirus vector particle, as well as a lentiviral vector particle comprising such a fusion protein. Gene correction using the disclosed lentiviral vector systems are being tested with respect to the betaglobin gene and the BCL11A gene (to treat sickle-cell disease) and will be used for induced pluripotent stem cell (iPS) generation. Potential Commercial Applications: • Sickle cell disease • gene therapy Development Stage: • Early stage Inventors: Naoya Uchida, Juan J. Haro Mora, John F. Tisdale (all of NHLBI) Relevant Publications: Demirci et al., Cytotherapy. 2018 Jul;20(7):899–910. doi: 10.1016/j.jcyt.2018.04.003. Epub 2018 May 30. Intellectual Property: HHS Reference No. E–165–2015; U.S Provisional Patent Application 62/236,223 filed October 2, 2015; International Patent Application PCT/US2016/054759 filed September 30, 2016, U.S. Continuation-in-Part Application 15/942,673 filed April 2, 2018 and European Patent Application 16782163.6 having an international filing date of September 30, 2016. Licensing Contact: Michael Shmilovich, Esq, CLP; 301–435–5019; shmilovm@mail.nih.gov. PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 Dated: October 4, 2018. Michael A. Shmilovich, Senior Licensing and Patenting Manager, National Heart, Lung, and Blood Institute, Office of Technology Transfer and Development. [FR Doc. 2018–22360 Filed 10–12–18; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Substance Abuse and Mental Health Services Administration Agency Information Collection Activities: Proposed Collection; Comment Request In compliance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995 concerning opportunity for public comment on proposed collections of information, the Substance Abuse and Mental Health Services Administration (SAMHSA) will publish periodic summaries of proposed projects. To request more information on the proposed projects or to obtain a copy of the information collection plans, call the SAMHSA Reports Clearance Officer on (240) 276– 1243. Comments are invited on: (a) Whether the proposed collections of information are necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Proposed Project: Technology Transfer Centers (TTC) Network Program Monitoring—NEW The Substance Abuse and Mental Health Administration’s (SAMHSA) will monitor program performance of its Technology Transfer Centers (TTCs). The TTCs disseminate current behavioral health and HIV services research from the National Institute on Drug Abuse, National Institute on Alcohol Abuse and Alcoholism, National Institute of Mental Health, Agency for Healthcare Research and Quality National Institute of Justice, and other sources, as well as other SAMHSA programs. To accomplish this, the TTCs develop and update state-of-the-art, E:\FR\FM\15OCN1.SGM 15OCN1

Agencies

[Federal Register Volume 83, Number 199 (Monday, October 15, 2018)]
[Notices]
[Page 51970]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-22360]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing in the U.S. to achieve 
expeditious commercialization of results of federally-funded research 
and development.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained 
by emailing the indicated licensing contact at the National Heart, 
Lung, and Blood, Office of Technology Transfer and Development Office 
of Technology Transfer, 31 Center Drive Room 4A29, MSC2479, Bethesda, 
MD 20892-2479; telephone: 301-402-5579. A signed Confidential 
Disclosure Agreement may be required to receive any unpublished 
information.

SUPPLEMENTARY INFORMATION: Technology description follows.

Lentiviral Protein Delivery System for RNA-Guided Genome Editing

    Available for licensing and commercial development is an HIV-1-
based lentiviral vector system for gene correction strategies involving 
a homologous recombination with a variation of the CRISPR/Cas9 system. 
Other such lentivirus-based vectors encode a guide RNA, which contains 
a specific sequence that recognizes a target gene, and a Cas9 
endonuclease, which cuts at the specific site. Such systems are being 
explored as potential therapies for certain hereditary diseases (e.g., 
sickle-cell disease). However, such systems present some problems due 
to constitutive expression of Cas9 endonuclease in lentiviral vector-
transduced cells and the large size of the Cas9 gene. The variation of 
this invention delivers the Cas9 endonuclease directly, instead of the 
gene encoding the protein. This system comprises (a) a lentivirus 
vector particle comprising a lentiviral genome which encodes at least 
one guide RNA sequence that is complementary to a first DNA sequence in 
a host cell genome, (b) a Cas9 protein, and optionally (c) a donor 
nucleic acid molecule comprising a second DNA sequence. In addition, 
the invention provides a host cell comprising the foregoing system, as 
well as a method of altering a DNA sequence in a host cell comprising 
contacting a host cell with the foregoing system. Alternatively, the 
invention also provides a fusion protein comprising a Cas9 protein and 
a cyclophilin A (CypA) protein, wherein the fusion protein binds to the 
lentivirus vector particle, as well as a lentiviral vector particle 
comprising such a fusion protein. Gene correction using the disclosed 
lentiviral vector systems are being tested with respect to the beta-
globin gene and the BCL11A gene (to treat sickle-cell disease) and will 
be used for induced pluripotent stem cell (iPS) generation.
    Potential Commercial Applications:

 Sickle cell disease
 gene therapy
    Development Stage:

 Early stage

    Inventors: Naoya Uchida, Juan J. Haro Mora, John F. Tisdale (all of 
NHLBI)
    Relevant Publications: Demirci et al., Cytotherapy. 2018 
Jul;20(7):899-910. doi: 10.1016/j.jcyt.2018.04.003. Epub 2018 May 30.
    Intellectual Property: HHS Reference No. E-165-2015; U.S 
Provisional Patent Application 62/236,223 filed October 2, 2015; 
International Patent Application PCT/US2016/054759 filed September 30, 
2016, U.S. Continuation-in-Part Application 15/942,673 filed April 2, 
2018 and European Patent Application 16782163.6 having an international 
filing date of September 30, 2016.
    Licensing Contact: Michael Shmilovich, Esq, CLP; 301-435-5019; 
[email protected].

    Dated: October 4, 2018.
Michael A. Shmilovich,
Senior Licensing and Patenting Manager, National Heart, Lung, and Blood 
Institute, Office of Technology Transfer and Development.
[FR Doc. 2018-22360 Filed 10-12-18; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.